Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

PROCEPT BioRobotics Corporation - Common Stock (NQ: PRCT )

58.42 +2.39 (+4.27%)
Streaming Delayed Price Updated: 12:20 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PROCEPT BioRobotics Corporation - Common Stock

< Previous 1 2 3 4 5 Next >
Nasdaq Gains 0.5%; TJX Earnings Top Estimates
Via Benzinga
Toll Brothers Posts Strong Earnings, Joins Keysight, Coty, TJX And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
PROCEPT BioRobotics Announces FDA Clearance of the HYDROS™ Robotic System, the Next-Generation, AI-Powered Platform for Aquablation® Therapy
Designed to improve efficiency, enhance surgeon and staff experience and deliver a more accurate and consistent treatment plan for better clinical outcomes 
From PROCEPT BioRobotics
Via GlobeNewswire
Cracking The Code: Understanding Analyst Reviews For PROCEPT BioRobotics
Via Benzinga
A Closer Look at 4 Analyst Recommendations For PROCEPT BioRobotics
Via Benzinga
Unveiling 4 Analyst Insights On PROCEPT BioRobotics
Via Benzinga
3 Robotics Stocks to Sell in August Before They Crash & Burn
Discover which robotics stocks to sell in August and why, ensuring you avoid potential market downturns and secure your investments. 
Via InvestorPlace
Is PROCEPT BioRobotics the Next Big Thing in Surgical Robotics?
Surgical robotics company PROCEPT BioRobotics Co. (NASDAQ: PRCT) developed the AquaBeam Robotic System for the treatment of benign prostatic hyperplasia 
Via MarketBeat
Why Intuitive Surgical Stock is Dominating the Medical Sector
Robotic surgery conjures up futuristic images of automated machines performing surgery on anesthetized human patients in an assembly line. However 
Via MarketBeat
PROCEPT BioRobotics® Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue and EBITDA Guidance
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics: Q4 Earnings Insights
Via Benzinga
Earnings Scheduled For February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
PROCEPT BioRobotics's Earnings: A Preview
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
PROCEPT BioRobotics to Report Second Quarter 2024 Financial Results on August 1, 2024
From PROCEPT BioRobotics
Via GlobeNewswire
You’ve Been Warned! 3 Robotics Stocks to Buy Now or Regret Forever.
While AI is grabbing all the headlines right now, forward-thinking investors are snapping up these robotics stocks before they blast off. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
PROCEPT BioRobotics Announces New CPT® Category I Code from the American Medical Association for Aquablation therapy
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024
From PROCEPT BioRobotics
Via GlobeNewswire
From Science Fiction to Reality: 3 Robotics Stocks for Automatic Riches
Artificial intelligence companies have already soared over the past year. These robotics stocks could be the next big thing. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
PROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock Conference
From PROCEPT BioRobotics
Via GlobeNewswire
Real-World, Long-Term Data Demonstrate Sustained Benefits of Aquablation Therapy for Men with Benign Prostatic Hyperplasia
Data from the Icahn School of Medicine at Mount Sinai and Potomac Urology presented at the 2024 AUA Annual Meeting highlight Aquablation therapy’s potential to become the new standard of care in BPH... 
From PROCEPT BioRobotics
Via GlobeNewswire
Intuitive Surgical Builds On Its Robotic Surgery Prowess. But Challengers Are Coming.
As new robotic surgery systems loom, Intuitive Surgical investors await a "game-changer." 
Via Investor's Business Daily
PRCT Stock Earnings: PROCEPT BioRobotics Beats EPS, Beats Revenue for Q1 2024
PRCT stock results show that PROCEPT BioRobotics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
PROCEPT BioRobotics Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
From PROCEPT BioRobotics
Via GlobeNewswire
Late Breaking Abstract Presented at the Japanese Urological Association Annual Meeting on Aquablation Therapy Outcomes for Men in Japan with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia
Japanese post market survey supports safety and efficacy of Aquablation therapy 
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Announces 12 Scientific Research Presentations on Aquablation Therapy for the Treatment of Benign Prostatic Hyperplasia at the 2024 AUA Annual Meeting
Presentations include first published experience report of same-day discharge in an ambulatory surgical center, real-world data outcomes and 5-year data comparison between two FDA trials 
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Corp. Announces Investor Event at 2024 AUA Annual Meeting in San Antonio, Texas
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics to Report First Quarter 2024 Financial Results on May 1, 2024 and Attend the 2024 Bank of America Healthcare Conference on May 15, 2024
From PROCEPT BioRobotics
Via GlobeNewswire
Truist Securities Maintains Buy Rating for PROCEPT BioRobotics: Here's What You Need To Know
Via Benzinga
PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2023 Results
From PROCEPT BioRobotics
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.